Literature DB >> 1696653

Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.

J L Mehta1, W W Nichols, T G Saldeen, V K Chandna, F A Nicolini, D L Lawson, M F ter Riet.   

Abstract

Release of superoxide radicals during the early phase of coronary reperfusion may result in degradation of endothelium-derived relaxing factor (EDRF), extension of myocardial injury, precipitation of arrhythmias, and stimulation of platelet aggregation. These factors may relate to the occurrence of ventricular fibrillation during reperfusion and coronary reocclusion following initial thrombolysis. This study was designed to examine the effects of concomitant administration of superoxide radical scavenger superoxide dismutase (SOD) with tissue plasminogen activator (tPA) compared to tPA alone (without SOD) in acute coronary thrombosis in anesthetized dogs. Dogs with a stable electrically induced coronary thrombus were randomly given intravenously tPA (0.75 mg/kg) alone or SOD bolus (2 mg/kg) followed by SOD (4 mg/kg) + tPA (0.75 mg/kg) over 20 min. tPA alone restored coronary blood flow in six of nine dogs (reperfusion rate of 67%) with time to reflow of 18.5 +/- 6.7 (mean +/- SD) min. Coronary reocclusion occurred spontaneously in four of six dogs with initial reperfusion (reocclusion rate of 67%). In contrast, SOD + tPA restored coronary blood flow in 9 of 12 dogs (reperfusion rate of 75%, not significant vs. tPA alone) with time to reflow of 11.3 +/- 4.8 min and coronary reocclusion occurred in only 3 of 9 dogs with reperfusion (reocclusion rate of 33%, not significant vs. tPA alone). Reperfusion arrhythmias were more frequent in dogs who received tPA alone compared to those who received SOD in addition to tPA (mean Holter-monitored PVC count of 730 vs. 12 beats/h, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696653     DOI: 10.1097/00005344-199007000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Myocardial Reperfusion Injury: From Bench to Bedside.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

Review 2.  Mitochondrial therapeutics for cardioprotection.

Authors:  Raquel S Carreira; Pamela Lee; Roberta A Gottlieb
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 3.  Autophagy, a process within reperfusion injury: an update.

Authors:  Bisharad Anil Thapalia; Zhen Zhou; Xianhe Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

4.  Ventricular arrhythmias and mortality associated with isoflurane and sevoflurane in a porcine model of myocardial infarction.

Authors:  Marta Regueiro-Purriños; Felipe Fernández-Vázquez; Armando Perez de Prado; Jose R Altónaga; Carlos Cuellas-Ramón; Jose M Ajenjo-Silverio; Asuncion Orden; Jose M Gonzalo-Orden
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-01       Impact factor: 1.232

5.  Does the antiarrhythmic effect of DMPO originate from its oxygen radical trapping property or the structure of the molecule itself?

Authors:  A Tosaki; R F Haseloff; A Hellegouarch; K Schoenheit; V V Martin; D K Das; I E Blasig
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

6.  The plasminogen activator system modulates sympathetic nerve function.

Authors:  Ulrich Schaefer; Takuji Machida; Sandra Vorlova; Sidney Strickland; Roberto Levi
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.